TipRanks
Chemomab Therapeutics (DE:2QV)
FRANKFURT:2QV
Germany Market
2QV
Chemomab Therapeutics
RESEARCH TOOLSreports

Chemomab Therapeutics (2QV) Income Statement

1 Followers

Chemomab Therapeutics Income Statement

Last quarter (Q2 2026), Chemomab Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Chemomab Therapeutics's net income was $-2.20M. See Chemomab Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Mar 23Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ -66.83K$ -57.77K$ -34.02K
Operating Expenses
$ 9.57M$ 14.74M$ 25.46M$ 28.53M$ 12.34M
Depreciation and Amortization
$ 70.00K$ 53.00K$ 67.00K$ 57.77K$ 34.02K
EBITDA
$ -9.50M$ -14.69M$ -25.39M$ -28.48M$ -12.34M
Operating Income
$ -9.57M$ -14.74M$ -25.46M$ -28.53M$ -12.38M
Other Income/Expenses
$ 572.00K$ 794.00K$ 1.24M$ 353.00K$ -111.08K
Pretax Income
$ -8.99M$ -13.95M$ -24.22M$ -28.18M$ -12.49M
Net Income
$ -8.99M$ -13.95M$ -24.22M$ -27.65M$ -12.49M
Per Share Metrics
Basic EPS
$ -1.42$ -68.80$ -8.22$ -9.68$ -4.80
Diluted EPS
$ -1.42$ -68.80$ -8.22$ -9.68$ -4.80
Weighted Average Shares Outstanding
 6.38M 202.91K 2.94M 2.84M 2.59M
Weighted Average Shares Outstanding (Diluted)
 6.38M 202.91K 2.94M 2.84M 2.59M
Currency in USD

Chemomab Therapeutics Earnings and Revenue History